Gossamer Bio, Inc. (NASDAQ: GOSS) Stock Competitors & Peer Comparison
See GOSS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GOSS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GOSS | $9.58 | +13.64% | 58.5M | -13.69 | -$0.70 | N/A |
| VRTX | $514.65 | +2.53% | 130.4B | 27.04 | $19.03 | N/A |
| MRNA | $242.08 | +6.69% | 96.6B | -29.70 | -$8.15 | N/A |
| REGN | $807.48 | +3.25% | 83.1B | 17.70 | $45.63 | +0.46% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $869.72 | +5.34% | 54.4B | 31.36 | $27.73 | N/A |
| RVMDW | $10.41 | +18.43% | 46.7B | -1.18 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $196.55 | +7.91% | 42.1B | -22.28 | -$8.82 | N/A |
| ONC | $384.50 | +3.87% | 41.1B | 67.69 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
GOSS vs VRTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, VRTX has a market cap of 130.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while VRTX trades at $514.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas VRTX's P/E ratio is 27.04. In terms of profitability, GOSS's ROE is +1.09%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GOSS is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
GOSS vs MRNA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MRNA has a market cap of 96.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MRNA trades at $242.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MRNA's P/E ratio is -29.70. In terms of profitability, GOSS's ROE is +1.09%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, GOSS is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
GOSS vs REGN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, REGN has a market cap of 83.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while REGN trades at $807.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas REGN's P/E ratio is 17.70. In terms of profitability, GOSS's ROE is +1.09%, compared to REGN's ROE of +0.14%. Regarding short-term risk, GOSS is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
GOSS vs VRNA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GOSS's ROE is +1.09%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, GOSS is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
GOSS vs ARGX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ARGX has a market cap of 54.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ARGX trades at $869.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ARGX's P/E ratio is 31.36. In terms of profitability, GOSS's ROE is +1.09%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, GOSS is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
GOSS vs RVMDW Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RVMDW has a market cap of 46.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RVMDW trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RVMDW's P/E ratio is -1.18. In terms of profitability, GOSS's ROE is +1.09%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, GOSS is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RVMDW's competition here
Seagen Inc. (NASDAQ: SGEN)
GOSS vs SGEN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GOSS's ROE is +1.09%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GOSS is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
GOSS vs RVMD Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RVMD has a market cap of 42.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RVMD trades at $196.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RVMD's P/E ratio is -22.28. In terms of profitability, GOSS's ROE is +1.09%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, GOSS is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
GOSS vs ONC Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ONC has a market cap of 41.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ONC trades at $384.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ONC's P/E ratio is 67.69. In terms of profitability, GOSS's ROE is +1.09%, compared to ONC's ROE of +0.14%. Regarding short-term risk, GOSS is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
GOSS vs ALNY Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ALNY has a market cap of 30.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ALNY trades at $230.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ALNY's P/E ratio is 41.57. In terms of profitability, GOSS's ROE is +1.09%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, GOSS is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
GOSS vs ROIV Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ROIV has a market cap of 25.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ROIV trades at $34.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ROIV's P/E ratio is -33.22. In terms of profitability, GOSS's ROE is +1.09%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, GOSS is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ROIV's competition here
Genmab A/S (NASDAQ: GMAB)
GOSS vs GMAB Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, GMAB has a market cap of 24B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while GMAB trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas GMAB's P/E ratio is 29.44. In terms of profitability, GOSS's ROE is +1.09%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, GOSS is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
GOSS vs UTHR Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, UTHR has a market cap of 23.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while UTHR trades at $553.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas UTHR's P/E ratio is 19.82. In terms of profitability, GOSS's ROE is +1.09%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, GOSS is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
GOSS vs INCY Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, INCY has a market cap of 23.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while INCY trades at $116.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas INCY's P/E ratio is 15.67. In terms of profitability, GOSS's ROE is +1.09%, compared to INCY's ROE of +0.30%. Regarding short-term risk, GOSS is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
GOSS vs BNTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BNTX trades at $91.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BNTX's P/E ratio is -11.82. In terms of profitability, GOSS's ROE is +1.09%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, GOSS is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
GOSS vs INSM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, INSM has a market cap of 20.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while INSM trades at $95.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas INSM's P/E ratio is -23.28. In terms of profitability, GOSS's ROE is +1.09%, compared to INSM's ROE of -1.11%. Regarding short-term risk, GOSS is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
GOSS vs BGNE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GOSS's ROE is +1.09%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, GOSS is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
GOSS vs DNA-WT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GOSS's ROE is +1.09%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, GOSS is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
GOSS vs EXEL Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, EXEL has a market cap of 16.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while EXEL trades at $64.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas EXEL's P/E ratio is 18.40. In terms of profitability, GOSS's ROE is +1.09%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, GOSS is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check EXEL's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
GOSS vs ASND Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ASND has a market cap of 14.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ASND trades at $234.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ASND's P/E ratio is -96.83. In terms of profitability, GOSS's ROE is +1.09%, compared to ASND's ROE of +1.90%. Regarding short-term risk, GOSS is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
GOSS vs NBIX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, NBIX has a market cap of 14.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while NBIX trades at $142.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas NBIX's P/E ratio is 20.52. In terms of profitability, GOSS's ROE is +1.09%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, GOSS is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check NBIX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
GOSS vs HALO Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, HALO has a market cap of 14.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while HALO trades at $124.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas HALO's P/E ratio is 23.20. In terms of profitability, GOSS's ROE is +1.09%, compared to HALO's ROE of +1.81%. Regarding short-term risk, GOSS is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check HALO's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
GOSS vs JAZZ Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, JAZZ has a market cap of 13.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while JAZZ trades at $213.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas JAZZ's P/E ratio is 7.97. In terms of profitability, GOSS's ROE is +1.09%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, GOSS is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
GOSS vs BBIO Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BBIO has a market cap of 13.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BBIO trades at $67.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BBIO's P/E ratio is -18.06. In terms of profitability, GOSS's ROE is +1.09%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, GOSS is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BBIO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
GOSS vs SMMT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, SMMT has a market cap of 12.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while SMMT trades at $16.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas SMMT's P/E ratio is -14.37. In terms of profitability, GOSS's ROE is +1.09%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, GOSS is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check SMMT's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
GOSS vs KRTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GOSS's ROE is +1.09%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GOSS is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
GOSS vs TECH Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TECH trades at $72.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TECH's P/E ratio is 37.41. In terms of profitability, GOSS's ROE is +1.09%, compared to TECH's ROE of +0.09%. Regarding short-term risk, GOSS is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
GOSS vs RNAM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GOSS's ROE is +1.09%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, GOSS is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
GOSS vs BMRN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BMRN has a market cap of 10.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BMRN trades at $56.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BMRN's P/E ratio is 27.13. In terms of profitability, GOSS's ROE is +1.09%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, GOSS is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
GOSS vs MDGL Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MDGL trades at $467.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MDGL's P/E ratio is -36.53. In terms of profitability, GOSS's ROE is +1.09%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, GOSS is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MDGL's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
GOSS vs PCVX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, PCVX has a market cap of 10.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while PCVX trades at $66.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas PCVX's P/E ratio is -8.68. In terms of profitability, GOSS's ROE is +1.09%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, GOSS is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check PCVX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
GOSS vs KRYS Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while KRYS trades at $325.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas KRYS's P/E ratio is 40.78. In terms of profitability, GOSS's ROE is +1.09%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GOSS is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
GOSS vs RXDX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GOSS's ROE is +1.09%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GOSS is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RXDX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
GOSS vs TWST Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TWST has a market cap of 9.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TWST trades at $142.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TWST's P/E ratio is -64.28. In terms of profitability, GOSS's ROE is +1.09%, compared to TWST's ROE of -0.30%. Regarding short-term risk, GOSS is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TWST's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
GOSS vs KYMR Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, KYMR has a market cap of 9.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while KYMR trades at $113.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas KYMR's P/E ratio is -35.46. In terms of profitability, GOSS's ROE is +1.09%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, GOSS is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check KYMR's competition here
10x Genomics, Inc. (NASDAQ: TXG)
GOSS vs TXG Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TXG has a market cap of 9.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TXG trades at $71.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TXG's P/E ratio is -121.12. In terms of profitability, GOSS's ROE is +1.09%, compared to TXG's ROE of -0.09%. Regarding short-term risk, GOSS is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TXG's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
GOSS vs IBRX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, IBRX has a market cap of 9.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while IBRX trades at $8.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas IBRX's P/E ratio is -9.04. In terms of profitability, GOSS's ROE is +1.09%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, GOSS is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check IBRX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
GOSS vs NUVL Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GOSS's ROE is +1.09%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GOSS is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
GOSS vs CRNX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CRNX's P/E ratio is -16.86. In terms of profitability, GOSS's ROE is +1.09%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GOSS is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
GOSS vs PTGX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, PTGX has a market cap of 8.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while PTGX trades at $137.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas PTGX's P/E ratio is 133.97. In terms of profitability, GOSS's ROE is +1.09%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, GOSS is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check PTGX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
GOSS vs CYTK Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CYTK has a market cap of 8.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CYTK trades at $63.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CYTK's P/E ratio is -8.86. In terms of profitability, GOSS's ROE is +1.09%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, GOSS is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CYTK's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
GOSS vs CAI Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CAI has a market cap of 8.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CAI trades at $31.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CAI's P/E ratio is 87.41. In terms of profitability, GOSS's ROE is +1.09%, compared to CAI's ROE of +0.19%. Regarding short-term risk, GOSS is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CAI's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
GOSS vs IMGN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GOSS's ROE is +1.09%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GOSS is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check IMGN's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
GOSS vs SYRE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, SYRE has a market cap of 8.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while SYRE trades at $91.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas SYRE's P/E ratio is -46.87. In terms of profitability, GOSS's ROE is +1.09%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, GOSS is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check SYRE's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
GOSS vs APGE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas APGE's P/E ratio is -31.19. In terms of profitability, GOSS's ROE is +1.09%, compared to APGE's ROE of -0.30%. Regarding short-term risk, GOSS is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
GOSS vs BPMC Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GOSS's ROE is +1.09%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GOSS is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BPMC's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
GOSS vs AXSM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, AXSM has a market cap of 8.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while AXSM trades at $159.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas AXSM's P/E ratio is -41.67. In terms of profitability, GOSS's ROE is +1.09%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, GOSS is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check AXSM's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
GOSS vs TGTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TGTX has a market cap of 8.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TGTX trades at $54.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TGTX's P/E ratio is 19.76. In terms of profitability, GOSS's ROE is +1.09%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, GOSS is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TGTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
GOSS vs ARWR Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ARWR has a market cap of 8.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ARWR trades at $58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ARWR's P/E ratio is -26.19. In terms of profitability, GOSS's ROE is +1.09%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, GOSS is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ARWR's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
GOSS vs CERE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CERE's P/E ratio is -16.47. In terms of profitability, GOSS's ROE is +1.09%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GOSS is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CERE's competition here
Abivax S.A. (NASDAQ: ABVX)
GOSS vs ABVX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ABVX has a market cap of 8.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ABVX trades at $92.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ABVX's P/E ratio is -15.17. In terms of profitability, GOSS's ROE is +1.09%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, GOSS is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
GOSS vs IONS Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while IONS trades at $45.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas IONS's P/E ratio is -13.88. In terms of profitability, GOSS's ROE is +1.09%, compared to IONS's ROE of -1.11%. Regarding short-term risk, GOSS is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
GOSS vs MTSR Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GOSS's ROE is +1.09%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, GOSS is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MTSR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
GOSS vs PRAX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, PRAX has a market cap of 7.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while PRAX trades at $264.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas PRAX's P/E ratio is -20.46. In terms of profitability, GOSS's ROE is +1.09%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, GOSS is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check PRAX's competition here
Merus N.V. (NASDAQ: MRUS)
GOSS vs MRUS Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GOSS's ROE is +1.09%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, GOSS is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
GOSS vs ACLX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GOSS's ROE is +1.09%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, GOSS is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ACLX's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
GOSS vs IOVA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, IOVA has a market cap of 6.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while IOVA trades at $14.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas IOVA's P/E ratio is -20.36. In terms of profitability, GOSS's ROE is +1.09%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, GOSS is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check IOVA's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
GOSS vs RETA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RETA's P/E ratio is -66.29. In terms of profitability, GOSS's ROE is +1.09%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GOSS is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
GOSS vs CNTA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GOSS's ROE is +1.09%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GOSS is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CNTA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
GOSS vs BLTE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, BLTE has a market cap of 6.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while BLTE trades at $154.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas BLTE's P/E ratio is -82.59. In terms of profitability, GOSS's ROE is +1.09%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, GOSS is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
GOSS vs RYTM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RYTM has a market cap of 6.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RYTM trades at $90.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RYTM's P/E ratio is -29.00. In terms of profitability, GOSS's ROE is +1.09%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, GOSS is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RYTM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
GOSS vs TERN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TERN's P/E ratio is -51.41. In terms of profitability, GOSS's ROE is +1.09%, compared to TERN's ROE of -0.14%. Regarding short-term risk, GOSS is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TERN's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
GOSS vs LGND Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while LGND trades at $306.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas LGND's P/E ratio is 33.63. In terms of profitability, GOSS's ROE is +1.09%, compared to LGND's ROE of +0.20%. Regarding short-term risk, GOSS is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check LGND's competition here
Immunovant, Inc. (NASDAQ: IMVT)
GOSS vs IMVT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, IMVT has a market cap of 5.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while IMVT trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas IMVT's P/E ratio is -10.14. In terms of profitability, GOSS's ROE is +1.09%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, GOSS is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check IMVT's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
GOSS vs KOD Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, KOD has a market cap of 5.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while KOD trades at $92.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas KOD's P/E ratio is -22.29. In terms of profitability, GOSS's ROE is +1.09%, compared to KOD's ROE of -2.73%. Regarding short-term risk, GOSS is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
GOSS vs CDTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GOSS's ROE is +1.09%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, GOSS is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
GOSS vs MIRM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MIRM trades at $85.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MIRM's P/E ratio is -5.85. In terms of profitability, GOSS's ROE is +1.09%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, GOSS is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
GOSS vs ABCM Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GOSS's ROE is +1.09%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GOSS is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
GOSS vs ISEE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GOSS's ROE is +1.09%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GOSS is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ISEE's competition here
CG Oncology Inc. (NASDAQ: CGON)
GOSS vs CGON Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CGON has a market cap of 5.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CGON trades at $61.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CGON's P/E ratio is -23.02. In terms of profitability, GOSS's ROE is +1.09%, compared to CGON's ROE of -0.25%. Regarding short-term risk, GOSS is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CGON's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
GOSS vs COGT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while COGT trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas COGT's P/E ratio is -14.81. In terms of profitability, GOSS's ROE is +1.09%, compared to COGT's ROE of -0.73%. Regarding short-term risk, GOSS is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check COGT's competition here
Veradermics, Incorporated (NYSE: MANE)
GOSS vs MANE Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MANE trades at $127.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MANE's P/E ratio is -40.50. In terms of profitability, GOSS's ROE is +1.09%, compared to MANE's ROE of -0.38%. Regarding short-term risk, GOSS is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MANE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
GOSS vs APLS Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas APLS's P/E ratio is 38.35. In terms of profitability, GOSS's ROE is +1.09%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GOSS is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
GOSS vs PTCT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while PTCT trades at $62.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas PTCT's P/E ratio is -27.00. In terms of profitability, GOSS's ROE is +1.09%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, GOSS is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check PTCT's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
GOSS vs ORKA Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ORKA has a market cap of 5.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ORKA trades at $79.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ORKA's P/E ratio is -40.77. In terms of profitability, GOSS's ROE is +1.09%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, GOSS is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ORKA's competition here
Erasca, Inc. (NASDAQ: ERAS)
GOSS vs ERAS Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ERAS trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ERAS's P/E ratio is -15.72. In terms of profitability, GOSS's ROE is +1.09%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, GOSS is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ERAS's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
GOSS vs SRRK Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, SRRK has a market cap of 5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while SRRK trades at $41.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas SRRK's P/E ratio is -11.99. In terms of profitability, GOSS's ROE is +1.09%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, GOSS is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check SRRK's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
GOSS vs TVTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TVTX trades at $52.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TVTX's P/E ratio is -116.22. In terms of profitability, GOSS's ROE is +1.09%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, GOSS is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TVTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
GOSS vs CRSP Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CRSP has a market cap of 4.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CRSP trades at $49.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CRSP's P/E ratio is -10.48. In terms of profitability, GOSS's ROE is +1.09%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, GOSS is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CRSP's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
GOSS vs DFTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while DFTX trades at $35.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas DFTX's P/E ratio is N/A. In terms of profitability, GOSS's ROE is +1.09%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, GOSS is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check DFTX's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
GOSS vs FOLD Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GOSS's ROE is +1.09%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, GOSS is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
GOSS vs AKRO Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GOSS's ROE is +1.09%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, GOSS is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
GOSS vs ALPN Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GOSS's ROE is +1.09%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GOSS is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ALPN's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
GOSS vs DNTH Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, DNTH has a market cap of 4.4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while DNTH trades at $78.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas DNTH's P/E ratio is -18.98. In terms of profitability, GOSS's ROE is +1.09%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, GOSS is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check DNTH's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
GOSS vs EWTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, EWTX has a market cap of 4.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while EWTX trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas EWTX's P/E ratio is -21.49. In terms of profitability, GOSS's ROE is +1.09%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, GOSS is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check EWTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
GOSS vs TNGX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TNGX trades at $25.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TNGX's P/E ratio is -30.43. In terms of profitability, GOSS's ROE is +1.09%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, GOSS is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
GOSS vs OPT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas OPT's P/E ratio is -1.52. In terms of profitability, GOSS's ROE is +1.09%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GOSS is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
GOSS vs PRTC Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GOSS's ROE is +1.09%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GOSS is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check PRTC's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
GOSS vs ARQT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ARQT has a market cap of 4.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ARQT trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ARQT's P/E ratio is 156.29. In terms of profitability, GOSS's ROE is +1.09%, compared to ARQT's ROE of +0.15%. Regarding short-term risk, GOSS is more volatile compared to ARQT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ARQT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
GOSS vs MRTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GOSS's ROE is +1.09%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GOSS is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
GOSS vs RLAY Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RLAY trades at $18.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RLAY's P/E ratio is -11.75. In terms of profitability, GOSS's ROE is +1.09%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, GOSS is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RLAY's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
GOSS vs ADPT Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ADPT has a market cap of 3.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ADPT trades at $24.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ADPT's P/E ratio is -59.56. In terms of profitability, GOSS's ROE is +1.09%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, GOSS is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ADPT's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
GOSS vs CPRX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CPRX's P/E ratio is 17.49. In terms of profitability, GOSS's ROE is +1.09%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GOSS is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
GOSS vs ABCL Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while ABCL trades at $11.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas ABCL's P/E ratio is -21.69. In terms of profitability, GOSS's ROE is +1.09%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, GOSS is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check ABCL's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
GOSS vs TLX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while TLX trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas TLX's P/E ratio is 116.49. In terms of profitability, GOSS's ROE is +1.09%, compared to TLX's ROE of +0.07%. Regarding short-term risk, GOSS is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check TLX's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
GOSS vs RYZB Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GOSS's ROE is +1.09%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GOSS is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
GOSS vs CBAY Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GOSS's ROE is +1.09%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GOSS is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check CBAY's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
GOSS vs AMLX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, AMLX has a market cap of 3.6B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while AMLX trades at $28.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas AMLX's P/E ratio is -19.18. In terms of profitability, GOSS's ROE is +1.09%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, GOSS is more volatile compared to AMLX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check AMLX's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
GOSS vs SWTX Comparison October 2026
Gossamer Bio, Inc. (NASDAQ: GOSS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GOSS stands at 58.5M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GOSS is priced at $9.58 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GOSS currently has a P/E ratio of -13.69, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GOSS's ROE is +1.09%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, GOSS is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for GOSS.Check SWTX's competition here